Cases & Deals

  • Home
  • Practices
  • Sanofi sells two established product portfolios to Neuraxpharm

Share

Sanofi sells two established product portfolios to Neuraxpharm

January 2023

Client(s) Sanofi

Jones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm. These portfolios include 17 molecules representing 38 brands marketed in over 50 countries, including Dogmatil, Tranxene and Trental.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.